Work

D7-02: Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR

Year: 2007

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1097/01.jto.0000283293.26207.0a

Authors: James Spicer, Hilary Calvert, Laura Vidal, Fathi Azribi, Rebecca Perrett, Mehdi Shahidi, Graham Temple, Andrew Futreal, Johann De Bono, Ruth Plummer

Institutions: Royal Marsden Hospital, Boehringer Ingelheim (United Kingdom), Wellcome Sanger Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W1985714655

FWCI: 2.85

Cites:

Cited by: 16

Related to: 10